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The use of aminoglycoside antibiotics began in 1940 with the discovery of streptomycin. 
The overuse and misuse of antibiotics has resulted in prevalent cases of antibiotic 
resistance.  The most common source of aminoglycoside resistance is the presence of 
enzymes that covalently modify the antibiotics at specific locations. One such enzyme, 
APH(3′)-IIIa [the aminoglycoside phosphotransferase three prime three a] conveys 
resistance by transferring the γ-phosphate [gamma phosphate] from ATP [adenosine 
triphosphate] onto the 3′ [three prime] carbon of the aminoglycoside antibiotic sugar ring. 
APH(3′)-IIIa has been shown to be flexible in solution and this flexibility is proposed to be 
responsible for its large substrate profile.  Upon binding the aminoglycoside, APH(3′)-IIIa 
adopts a well-defined structure. All previous experiments were conducted in vitro. Here, 
various aspects associated with the flexibility of APH(3′)-IIIa are further examined in vivo. 
In-cell NMR [nuclear magnetic resonance] experiments are used to determine the protein 
dynamics of APH(3′)-IIIa in the crowded environment of the cell. Next, the flexibility of 
APH(3′)-IIIa is examined when binding more rigid aminoglycoside antibiotics: sisomicin 
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Chapter I: Introduction 
A. Aminoglycoside Antibiotics 
i. Aminoglycoside general use and chemical structure 
Penicillin was the first antibiotic to be discovered and was used clinically in 1928. 
However, the term antibiotic was not used until 1941[3-5]. After the discovery of beta 
lactam antibiotics, aminoglycoside family antibiotics were the next to be discovered with 
streptomycin in 1940 [4]. Aminoglycosides can be used to treat both gram-positive and 
gram-negative bacterial infections. Aminoglycosides are known for treating tuberculosis as 
well as other serious infections; however, because of potent side effects their clinical use 
must be heavily monitored [6]. Currently, gentamicin, tobramycin, amikacin, streptomycin, 
neomycin, and paromomycin are approved by the US Food and Drug Administration for 
clinical use in the United States [7, 8]. Additional uses of aminoglycosides include the 
inhibition of HIV virus reproduction and treatment of some genetic diseases [9, 10] 
Streptomycin, like other aminoglycosides, is derived from soil bacteria and is synthesized 
from sugar monomers [11].  Aminoglycoside antibiotic structures contain a variety of sugar 
rings, with various modifications. The wide use of these antibiotics is possible in part 
because of variety in their chemical structures [4].  
Most aminoglycosides are separated into one of two major groups, kanamycins and 
neomycins.  The unprimed ring or aminocyclitol is the nucleus of both groups and is a 2-
deoxystreptamine (2-DOS) ring linked by glycosidic bonds to other amino sugar rings 
(Figure 1) [12]. Aminoglycosides that are considered a neomycin contain a 4,5-
disubstituted central 2-DOS ring, whereas those identified as a kanamycin contain a 4,6-
disubstituted central 2-DOS ring [13]. There are numerous modifications that can be made 
to the various sugar rings to individualize the general backbone of the two groups of 
aminoglycosides, including but not limited to additional sugar rings, methyl groups, 





Figure 1: Aminoglycoside antibiotic structures of kanamycin (top) and neomycin 
(middle) family representatives.  Unprimed (2-DOS), primed and double primed 
rings are depicted.  Gentamicin family representatives, gentamicin B, sisomicin and 
netilmicin are shown at the bottom. Gentamicin B is identical to sisomicin except 
that gentamicin B contains a saturated diamino primed ring, instead of an 
unsaturated diamino primed ring (shown).  
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ii. Mechanism by which aminoglycosides cause cell death  
 Aminoglycosides cause miscoding during protein synthesis which results in a 
compromised cell membrane and a reduction in cell viability [14]. First, aminoglycosides 
bind the aminoacyl-tRNA decoding site (A-site) on the 16S RNA subunit of the ribosome 
[15-17].  Crystal structure of the unbound 30S ribosomal subunit reveals that the A-site 
contains an internal loop in which two adenine side groups are facing into the helix. During 
translation, when the correct anticodon matches the codon of the mRNA, the two adenine 
side groups flip to face the outside of the helix. This conformational change dictates the 
continuation of translation [18]. The crystal structure of the 30S subunit bound by 
paromomycin reveals that the aminoglycoside inserts its primed ring into this helix, forcing 
the two adenines to pucker out from the helix [18].  The central unprimed ring of 
paromomycin interacts with several conserved base pairs in the A-site [15]. Therefore, the 
neamine portion (the prime and unprimed rings) of the aminoglycoside interferes with 
translation processes by binding structurally conserved regions of 16S ribosomal RNA 
(rRNA). This stabilizes a conformation of the A site which allows for incorrect ribosomal 
translation of proteins [16, 18]. The electrostatic forces between the positively charged 
aminoglycosides to the negatively charged RNA molecules drive this binding event [18].  
Aminoglycosides have a ten-fold higher affinity to prokaryotic rRNA as compared to 
eukaryotic rRNA, providing a level of specificity for prokaryotic rRNA [15].    
B. Aminoglycoside Modifying Enzymes 
i. Nomenclature and modification sites  
Antibiotic resistance is an increasing problem in clinical settings [19]. Resistance to 
aminoglycosides can occur via three main mechanisms: chemical modification of the 
aminoglycoside, chemical modification of the rRNA, and point mutations of the A-site [6, 
18]. The main method of resistance is chemical modification of aminoglycosides by 
inactivating enzymes. The first enzyme, β-lactamase, found to provide resistance via 
chemical modification to β-lactam antibiotics was discovered in 1940 [20]. Today there are 
over fifty known enzymes that chemically modify aminoglycosides, termed aminoglycoside 
modifying enzymes (AGMEs) [19].  Each of these enzymes modifies the aminoglycoside at a 
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specific location, and is generally able to catalyze only one type of modification: 
phosphorylation, acetylation and adenylation. [19].  Therefore AGMEs are named according 
to site and type of modification made to the aminoglycoside. Enzymes that facilitate one of 
the listed modifications are termed phosphotransferases (APH), acetyltransferases (AAC), 
or nucleotidyltransferases (ANT) respectively. AGMEs are then further characterized by the 
location of the modification that they facilitate, for instance APH(3′)IIIa phosphorylates the 
hydroxyl group attached to the C-3 on the primed ring of the aminoglycoside antibiotic 
[21]. Because there are several AGME’s that catalyze the same modification, they are then 
further characterized by discovery and resistance profile [19].    
Chemical modifications made to an aminoglycoside reduce its binding affinity for the A-site 
by creating steric hindrance or unfavorable electrostatic interactions with the 30S rRNA 
subunit. For instance, the addition of a negatively charged phosphate group alters the 
attraction of the aminoglycoside for the negatively charged A-site [15]. Chemical 
modifications at the various sites on aminoglycosides decrease their binding affinity for the 
A-site to varying degrees. The aminoglycoside side groups important to A-site binding are 
also important for recognition by AGMES. This makes designing drug targets exclusively for 
either the A-site or AGME difficult. 
ii. Substrate (aminoglycoside) promiscuity 
Aminoglycoside modifying enzymes are promiscuous. If the AGME is able to bind a large 
number of aminoglycoside substrates; thereby seeming to exhibit indiscriminant selectivity 
of substrates, it is termed highly promiscuous. For example, APH(3′)-IIIa would be termed 
highly promiscuous because it is able to bind and modify to over a dozen aminoglycosides. 
AGMEs that are able to efficiently modify only a few aminoglycoside substrates are 
considered to have a low promiscuity.  AAC(3)-IIa for instance is unable to provide 
resistance against neomycins, therefore AAC(3)-IIa has a lower promiscuity than APH(3′)-
IIIa. Other AGMEs, such as AAC(3)-IVa have even more restricted substrate promiscuities 
[19].       
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C. Introduction to APH(3′)-IIIa 
As mentioned before, each AGME has a specific binding profile as well as binding 
mechanism. This thesis will focus on AGME APH(3′)-IIIa which will be referred to as APH. 
The structure and mechanism of APH will be described here; however additional AGMEs 
with differing structures and mechanisms will be discussed in lesser detail in chapters III 
and IV.  
APH is a 31 kDa protein produced by gram-positive cocci such as Staphylococci and 
Enterococci. Functionally, APH catalyzes an adenosine triphosphate (ATP) dependent 
phosphorylation of hydroxyl groups at the 3′ position of aminoglycosides [1]. APH is known 
to modify aminoglycosides: kanamycin A, kanamycin B, neomycin, paromomycin, 
ribostamycin, lividomycin (modifies the 5″ hydroxyl), butirosin, gentamicin B, amikacin, 
and isepamicin, but binds additional aminoglycosides that do not contain a 3′ hydroxyl 
group such as tobramycin [19, 22].  
iii. APH structure 
APH is found as either a monomer or a covalent dimer, linked by two disulfide bridges: 
Cys19 is linked to Cys156 of the partner molecule and vice versa [1]. Crystal structure of 
APH solved by Hon et al. shows APH as a dimer, with each monomer bound to an ADP 
molecule as well as two magnesium ions (Mg2+) and several solvent molecules. The 
monomers are linked in a head-to-tail-tail-to-head orientation [1]. The two active sites face 
each other and are separated by approximately 20 Å [1]. However, in physiological 
conditions APH is most likely to be found as a monomer [23]. In experiments described 
here, purified APH is kept in a monomeric state by incubation with dithiothreitol (DTT), a 
redox reagent that reduces disulfide bonds of exposed cysteine residues. APH is then 
stored in a Tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl) containing buffer 
which also reduces disulfide bonds but is considered more stable than DTT [24].  
Although APH shares very little sequence homology with other protein kinases, it contains 
several structural features associated with protein kinases. APH is made up of two lobular 
regions: the N-terminal region and the C-terminal region [1]. The N-terminal region is 
made up of 94 residues and is the smaller lobe. The larger C-terminal lobe is made up of 
157 residues. The lobes are connected by a stretch of twelve residues that form a short β 
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strand and an α helix [1].   The N-terminal lobe contains a five-stranded antiparallel β sheet 
(strands labeled β1-β5) with an α helix located between strands 3 and 4; following the β 
sheet is another short helix.  The structure of the N-terminal lobe region as well as the 
linking region is consistent with other eukaryotic-type protein kinases. However, APH lacks 
the highly conserved G-X-G-X-X-G motif seen in typical protein kinases located in between 
beta strands β1 and β2 [1]. The C-terminal lobe region is subdivided into a central core 
region, insert region, and C-terminal region. The central core is made up of helices α4 and 
α5 with a hairpin-shaped loop that contains a short antiparallel β sheet.  This region also 
shares conformational similarity with other protein kinases [1]. The insert region consists 
of two helices (αA and αB) connected by a 19-residue loop. The C-terminal region is made 
up of two helices (αC and αD). Both the insert region and the C-terminal region of the C-
terminal lobe differ from the typical protein kinase C-terminal fold. A topological depiction 
of the APH structure is given in Figure 2.  
The 60 residue insert region of APH is particularly interesting. Much smaller in most 
protein kinases, this region is responsible for specificity and selectivity of substrates. X-ray 
crystallography showed that the insert region is located in front of the active site, and is in 
a position to interact with aminoglycoside substrates of APH [1].  
i. ATP and Aminoglycoside binding sites 
 Binding of substrates with APH follow Theorell-chance mechanism, meaning that there is 
an order to substrate binding. ATP and Mg2+ ions bind the enzyme first, followed by the 
aminoglycoside. After the phosphate transfer from ATP to the antibiotic, the 
phosphorylated aminoglycoside is released followed by the release of ADP [23, 25]. At 
typical intracellular ATP concentrations the ATP binding site of APH will be saturated [26].  
All aminoglycoside phosphotransferase enzymes share a common active site motif. The 
ATP active site is found in the linking region between the N-terminal lobe and the C-
terminal lobe. [23].  According to crystal structures, the adenine ring of ATP is buried, 
forming several interactions with both N-terminal lobe and C-terminal lobe residues. The 
α-phosphate interacts with two water molecules, highly conserved residue Lys44, as well 
as the first Mg2+. The β-phosphate was found to interact with one water molecule, Lys44, 
Ser27 as well as the second Mg2+. The donor phosphate or γ-phosphate coordinates with 
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both magnesium ions [23]. The two magnesium ions facilitate the correct orientation of the 








Figure 2: structure of APH, high lighting the GXGXXG region (red), flexible binding loop 
(orange), insert region (purple) and tethering segment (yellow). Topological diagram of 
the secondary structure highlights the same regions and provides a comparison to typical  
eukaryotic protein kinase secondary structure (shown in grey) [1]. 
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Crystal structure analysis of apo APH compared to ADP bound APH revealed the 
interaction of a short loop region (residues 22-29), between β1 and β2, with the binding of 
the ATP molecule.  These residues occupy part of the nucleotide binding region in the 
absence of nucleotide, but shift outward in the presence of nucleotide [23].    
The same electrostatic forces that are important for the binding of the aminoglycoside to 
rRNA are also important in the binding of aminoglycosides to APH. The aminoglycoside 
binding pocket contains three aspartic acid residues, five glutamic acid residues and the C-
terminal carboxylic acid group. The positively charged aminoglycosides are attracted to the 
excess negative charge of APH in the region of its binding site [15]. Crystal structures of 
APH bound with ADP and kanamycin A or neomycin B showed that the flexible loop region 
from 147-170 moves approximately 10 angstroms from unbound to bound state. It is 
thought that Glu157, Asn158, and Glu160 from this loop region interact with the 
aminoglycoside substrate [27]. It is predicted that similar to other protein kinases, an 
aspartate (Asp190) is responsible for the catalytic activity of deprotonating the substrate 
hydroxyl group. It has been suggested that there is a direct transfer of the phosphate group 
onto the aminoglycoside, however the exact mechanism by which APH phosphorylates its 
bound aminoglycoside substrate is still unknown [23]. 
ii. Dynamic nature of APH in solution 
In previous work done by Norris et al. it was shown that in the absence of ligand, APH has a 
highly overlapped heteronuclear single quantum coherence (15N-1H HSQC- henceforth 
will be referred as HSQC) nuclear magnetic resonance (NMR) spectrum [28]. This 
overlapped spectrum indicates that several backbone amide groups are in very similar 
chemical environments, suggesting that the apo enzyme is flexible and may be adopting 
multiple confirmations in an aqueous solution.  Hydrogen-deuterium exchange studies with 
APH revealed that after 15 minutes of exposure to deuterium oxide (D2O), 80% of the 
backbone amides had fully exchanged and were 100% exchanged after 15-20 hours [28]. 
When APH is part of a binary complex with kanamycin A the HSQCH2O spectra is 
dramatically different as compared to the apo form. When bound to antibiotic, 
approximately 85% of all resonances were well-resolved [28, 29]. The chemical shifts seen 
with the binary APH-aminoglycoside complex indicated that APH adopts a more well-
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defined structure when bound to aminoglycoside antibiotics (Figure 3) [28]. Hydrogen 
deuterium exchange experiments done with APH bound to either kanamycin A or 
neomycin B showed significant increase in the protection of backbone amide groups [28]. 
There were also differences in protection of specific amino acids between the bindings of 
kanamycin A or neomycin B. This indicated that the effect of ligand binding to APH resulted 
in different structural and dynamic properties dependent upon the ligand [28].  
iii. Kinetics and thermodynamics of ligand binding 
When discussing the complexes of APH, the term binary will refer to the complex of either 
antibiotic or adenylmethylenediphosphnate (AMPPCP) bound to AGME. AMPPCP is a non-
hydrolysable analog of ATP. The term ternary will refer to the complexes formed with APH, 
aminoglycoside, Mg2+ and AMPPCP. In theory, this not a ternary complex because two Mg 
ions bind to APH therefore, equaling a total of five binding partners. For the purpose of this 
study Mg2+ was kept at saturating levels in both samples during titrations when AMPPCP 
was used. Therefore the only one component is binding to the formed complex of the other 
four. The order of addition is found in the ternary nomenclature, for example the formation 
of ternary complex APH-antibiotic-Mg-AMPPCP was created by adding Mg-AMPPCP into 
APH-antibiotic-Mg complex.   
Binary thermodynamic studies done of APH binding to various aminoglycoside partners 
revealed that, in general, binding is enthalpically driven which is compensated for by an 
unfavorable entropic contribution [30, 31]. The overall gain in structure upon the binding 
of aminoglycoside to APH correlates well as a potential source for the unfavorable entropy 
(∆S). Published negative enthalpy (∆H) values associated with the formation of the binary 
complex indicate that formation is driven by favorable binding contacts such as polar, 
electrostatic, van der Waals forces and hydrogen bonds [30].  The large exothermic heat of 
association is able to compensate for the unfavorable entropy, therefore association of APH 
and all aminoglycosides have a favorable Gibb’s energy change (∆G). Isothermal titration 
calorimetry (ITC) of ternary enzyme-CaATP-aminoglycoside complexes revealed that when 
CaATP is present, binding of the aminoglycoside to APH is generally tighter [30]. As stated 
previously, APH exhibits a Theorell-Chance kinetic mechanism of binding; in this case the 
binding of CaATP seems to encourage binding of aminoglycoside.   
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APH is the most well-studied aminoglycoside modifying enzyme to date, however the exact 
mechanism by which it is able to modify such a large number of substrates remains to be 







Figure 3: Partial image used with permission of Norris et al.  HSQC NMR spectra of APH 
complexes. APH in its apo (left) and binary APH-tobramycin (right) forms are shown. All 




Chapter II: In-cell Nuclear Magnetic Resonance 
A. Background  
i. In-cell nuclear magnetic resonance spectroscopy 
The first NMR spectrometer became commercially available in 1961 with the 60 megahertz 
(MHz) Varian A-60 [32].  Typical NMR experiments involve the examination of small 
molecules and macromolecules in vitro, currently NMR techniques are also being used to 
determine the dynamics of proteins in vivo. Termed “in-cell” NMR spectroscopy, this 
technique is valuable as it uses NMR to investigate the conformation as well as the 
dynamics of proteins while they are in their native cellular environment.  The cellular 
environment is crowded, with macromolecular concentrations as high as 400 g/l. Most 
proteins are studied outside the cell with concentrations of 10 g/l or less [33].  There can 
be discrepancies between protein dynamics studied in vitro by NMR and those that are 
studied in the more dilute in vivo environment. Therefore the use of in-cell NMR techniques 
provides a unique opportunity to examine the naturally found dynamics of a protein. 
However, it is unlikely that in-cell NMR spectroscopy will replace in vitro NMR experiments 
as the latter offers sharper line widths and more stable conditions for experiments over 
longer periods of time. In-cell NMR requires that the protein of interest be labeled, as well 
as contained in an intact live cell.  Labeling is required to make the protein of interest 
distinguishable from the resonances of all other proteins in the cell. The most common 
forms of labeling are with 13C, 15N, and 19F [34]. Labeling requires the use of expression 
vectors to overexpress the protein of interest in labeled media.  
 In more commonly used NMR experiments, proteins are able to tumble freely in solution 
and have rotational correlation times that are less than a few nanoseconds [34].  Increasing 
viscosity of a solution results in a slowed tumbling of the protein and in a broadening of the 
resonance lines. Proteins in the cell are subjected to environments of higher viscosity and 
therefore a broadening of resonance lines is to be expected. This broadening results in a 
loss of resonances of more structured portions of the protein.  Larger line widths 
associated with in-cell NMR result in greater peak overlap relative to their in vitro 
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counterpart. Therefore it is important to only compare changes occurring in different in-
cell experiments, rather than to in vitro experiments.  In-cell protein leakage is a common 
problem associated with in-cell NMR.  As the cells are stressed they experience cell damage 
and the labeled protein is released (protein leakage). It was previously reported that 
leaked proteins will cause artifacts, therefore careful measures must be taken to ensure 
that the cells are healthy [33]. Heteronuclear multiple-quantum coherence (HMQC) 
experiments are used with in-cell experiments for their quickness of completion with 
relatively little loss in peak resonance.     
ii. Structural dynamics of APH  
Previous H/D exchange NMR experiments showed that the APH backbone amides exchange 
rapidly, confirming that APH is flexible in solution [28]. This flexibility is hypothesized to 
allow APH to be highly promiscuous. In 2010 the backbone resonance assignments were 
made for the APH-tobramycin complex [29].  This work confirmed and expanded on 
previous NMR work with APH; the 7.5-9 ppm peak range seen with the apo complex 
increases to 115-121 ppm range when bound to tobramycin making it possible to assign 
more of the resonances [28].  
The crowded nature of the cell can be to an extent mimicked by the addition of crowding 
agents such as bovine serum albumin (BSA), glucose or albumin [34]. Preliminary data 
showed that with the addition of BSA, the HSQC NMR spectra remained fairly overlapped as 
compared to the HSQC NMR spectra of apo APH complex without BSA. This indicates that 
even in a crowded environment, 15N labeled APH retains much of its flexibility, shown by 
the retention of highly overlapped spectra (Figure 4).   
Neither crystallography nor typical NMR studies have looked at the enzyme’s dynamics in 
its natural environment. New NMR techniques have provided a way to examine protein 
dynamics while still contained in the cell. Although this method is still being developed, it is 
useful when determining the effects of crowding on a protein’s dynamics. Therefore, in-cell 
NMR techniques will be used to look at the structural dynamics of APH when 
overexpressed in Escherichia coli cells.  
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iii. Aminoglycoside in-cell effects 
Aminoglycoside antibiotics enter both gram-positive and gram-negative bacteria via three 
distinct steps. First is the self-promoted uptake of the antibiotic by binding onto anionic 
compounds like phospholipids to promote an increase in uptake of the antibiotic into the 
periplasmic space [12, 35]. Next, the electron transport system creates a electrochemical 
gradient across the mitochondrial membrane, which facilitates the uptake of antibiotics 
into the cytoplasm by unidentified transporters [12]. The aminoglycoside antibiotics then 
cause errors in protein synthesis. The mistranslated membrane proteins then allow for 
increased uptake in antibiotics which further accelerates cell death [12, 14, 15, 18]. In 
order to see conformational changes associated with binding of APH to an aminoglycoside 
in the cell, the choice and amount of aminoglycoside will need to be optimized. The amount 
of aminoglycoside will need to be low enough to maintain cell viability and therefore cause 
low amounts of cell leakage, but high enough concentrations so that APH will be in its 
bound form.   
B. Experimental Procedures 
i. Chemicals 
Isopropyl-β-D-thiogalactopyranoside (IPTG) was purchased from Inalco Spa (Milan, Italy), 
and 99.9% deuterium oxide was obtained from Cambridge Isotope laboratories (Andover, 
MA). 15N enriched salts were also purchased from Cambridge Isotope Laboratories 
(Andover, MA). All other general chemicals and aminoglycosides were of highest available 
purity and were obtained from either Sigma-Aldrich (St. Louis, MO) or Fisher Scientific 
(Pittsburgh, PA).   
ii. Growth of 15N labeled APH cells  
Following closely to methods previously used, agar plates (10 g/l tryptone, 5 g/l yeast 
extract, 10 g/l NaCl, 15 g/l agar) containing 100 µg/ml ampicillin (amp) and 50 µg/ml 
kanamycin A were streaked with transformed E.coli [33, 34]. The transformed cells 
contained a pET-15b vector with the genetic information to overexpress APH, generously 
provided by Dr. Amber Bible and Dr. Adrianne Norris.  Ampicillin (AMP), while not an 
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aminoglycoside is used because this particular expression vector codes for ampicillin 
resistance via the expression of the enzyme β-lactamase. Resistance to ampicillin, as well as 
overexpression of APH which provides resistance to kanamycin A, ensured that the 
colonies grown contained the correctly cloned pET-15b vector [36]. An extra agar plate 
was created each time and contained both antibiotics, but was not streaked. This was done 
as a negative control.  Plates were inverted and incubated overnight at 37 °C. The next 
afternoon, a single colony was inoculated into approximately 15 mls fresh Luria Broth (10 
g/l tryptone, 5 g/l yeast extract, 10 g/l NaCl) containing 100 µg/ml AMP and incubated at 
37 °C with agitation of 200 RPM overnight.  The following morning the overnight culture 
was used to seed a fresh 100 ml Luria Broth (LB) and AMP culture.  The fresh culture was 
then allowed to grow at 37 °C with agitation until it reached 0.4 OD600.  To ensure that the 
cells used for in-cell NMR were healthy, the cultures were kept at cell concentrations lower 
than 0.5 OD600. This ensured that the cells were actively growing and not in stationary or 
death phase when induced.   
Cells were then transferred to 50 ml centrifuge tubes where they were spun at 1600 xg for 
15 minutes. The Luria broth was then decanted and cells were suspended in 70 ml of 15N 
labeled M9 media.  Ingredients for 1 Liter final volume of M9 minimal media are as follows: 
7 g/l sodium phosphate, 3.5 g/l monobasic potassium phosphate, .5 g/l NaCl, 1 ml trace 
metal solution, 1 ml 1M MgSO4, 100 µl 1M CaCl2, 70 µl .5M FeCl2, 25 µl 2% thiamine, 4 g 
glucose, 1 g 15NH4Cl2, and 100 µg/ml AMP [28]. The M9 minimal media is filter sterilized 
and kept at 4 °C until use. The trace minerals solution was made with a final volume of 1 
liter and contained 2.86 g H3BO3, 1.81 g MnCl2*7H2O, 0.23 g ZnSO4*7H2O, 0.39 g 
Na2MoO4*2H2O, 0.079 g CuSO4*5H2O, and 0.0494 g Co(NO3)2*6H2O, which was filter 
sterilized and kept at 4 °C. The culture was placed at 37 °C with agitation for 10 minutes 
before adding 700 µl of 0.024 g/ml IPTG. The time delay was to allow the cells to acclimate 
to the new media and restart growth. Cells were not initially grown in 15N labeled media so 
that only the induced protein would be labeled. IPTG mimics allolactose in the cell; it binds 
onto the lac repressor which then allows for transcription of APH which is located in the lac 
operon. IPTG is not hydrolyzed by β-galactosidase and therefore remains at a constant 
concentration, encouraging consistent overexpression of APH. An induction time of 4 hours 
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was initially used to produce an increased expression of APH. High concentrations of APH 
are desirable, as it is difficult to get a good signal from the 15N labeled protein in the 
crowded environment of the cell. However, because of the reduced cell viability at high 
induction times, the induction time was later reduced to 30 minutes. Cells were then 
transferred to clean 50 ml centrifuge tubes and spun at 1600 xg for 10 minutes, which 
produced a very fragile pellet of cells. The M9 media supernatant was decanted off and cells 
were then gently suspended in 1200 µl of 7-10% deuterated PBS buffer (3.2 mM Na2HPO4, 
0.5 mM KH2PO4, 1.3 mM KCl, 135 mM NaCl with added 7-10% volume D2O pH 7.4) by 
gentle swirling.   
iii. Cell assays 
To determine the best condition in which to perform in-cell NMR, LIVE/DEAD cell assays 
were used to analyze cell viability. Cells were grown under several different conditions and 
induction times, they were then stained according to the LIVE/DEAD BacLight Bacterial 
Viability Kit protocol[37]. Although the chemical structures of these stains are copy-
righted, it is well documented that the SYTO 9 dye is a green fluorescent nucleic acid stain 
that labels the cell membrane. The red-fluorescent nucleic acid stain, propidium iodide, is 
able to penetrate cells with damaged cell membranes [37].  The emission wavelengths for 
the fluorescent stains are 500 nm for the SYTO 9, and 635 nm for propidium iodide. Cells 
that fluoresced at 500 nm were considered alive and cells that fluoresced at 635nm were 
considered dead. Using a Zeiss Observer .Z1 microscope, cells were visualized using oil 
emersion 63 x objective, which has a resolution of 0.24 micrometers. Cells were observed 
under differential interference contrast (DIC) filter as well as filters for green fluorescent 
protein (GFP) and red fluorescent protein (RFP).  The GFP filter collects emission 
wavelengths at 510 nm and the RFP filter collects emission at 700 nm. Pictures were taken 
of each condition using a Hamamatsu ORCA-ER digital camera attached to the microscope, 
and saved in OpenLab5 software.  All DIC, GFP and RFP images were taken sequentially 
after switching the excitation wavelength. Images were then analyzed via Image J software 
where live and dead cells were counted on each image [38]. The numbers of live or dead 
cells were analyzed and graphed using Graphpad Prism software.  
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iv. Cell lysis  
Small sample size prevented use of the French press to lyse the cells [30]. Sonification was 
also not applicable as it was previously shown to deactivate APH. Therefore cell lysis trials 
were done using various combinations of freeze-thaw cycles and the addition of lysozyme. 
Preparation of cells began according to the method outlined in section ii above, with the 
following variations: unlabeled ammonium chloride was used during induction and cells 
were suspended into 10 mls of non-deuterated PBS buffer. The sample was then separated 
into ten 1ml aliquots.  Each aliquot was subjected to a different combination of freeze thaw 
cycles by freezing in liquid nitrogen and thawing at room temperature and addition of 
lysozyme. Lysozyme was used because of its known ability to damage bacterial cell walls 
[39]. The protocol for using lysozyme in cell lysis calls for a heat shock of the sample in 
order help break apart the cell wall, however heat above 45 °C denatures purified APH 
protein therefore in order to have fully active enzyme heat shock was not used in the 
varying lysis conditions [40].  Among the conditions tried, several included adding 
lysozyme preheated as well as unheated.  Each aliquot was then centrifuged at maximum 
speed for 2 minutes.  38 µl of supernatant from each sample was combined with 12 µl 4% 
SDS loading dye and loaded into a lane on a 10% acrylamide gel [41].  The gel ran at 85 
volts for approximately 45 minutes.  It was then stained it for 20 minutes, followed by 
destain for 1.5 hours. Methods followed and materials used were in accordance with 
previously published work [41, 42].    
v. In-cell nuclear magnetic resonance 
For in-cell NMR experiments, 1200 µl of prepared whole cell sample was transferred to a 
NMR tube.  The whole cell sample was then inserted into the 600 MHz NMR spectrometer. 
After appropriate calibrations are performed, a 1 hour HMQC experiment with 32 scans 
was executed. Upon completion of the experiment, cells were transferred to a 
microcentrifuge tube and spun in a table top centrifuge at 2,000 RPM for 10 minutes. 600 µl 
of the supernatant was then transferred to a clean NMR tube and an identical HMQC 
experiment was run after re-calibrating the NMR machine. The supernatant is run 
separately because it must be shown that the protein has not leaked from the cell. If the 
protein has leaked into the extracellular space it is not subjected to the same crowding 
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effects as the in-cell protein. The pelleted cells are then lysed according to our determined 
protocol of alternative freeze-thaw cycles. The cell debris was then centrifuged for 10 
minutes at 13.2 RPM. Upon cell lysis, the labeled APH protein is freed from the cell and 
located in the cell lysate. 600 µl of the cell lysate is transferred to a clean NMR tube and an 
identical HMQC experiment is performed. Spectra were processed in nmrDraw and 
exported to Sparky for analysis and display [43, 44]. Adobe Photoshop software was used 
to invert images to change the background to white. 
vi. Empty vector in-cell nuclear magnetic resonance 
An important negative control was in-cell NMR performed on cells containing an empty 
vector. This was done to determine the amount of 15N that is nonspecifically incorporated 
into the cell. First, competent E.coli cells were transformed with an empty pET-15b vector. 
Proper transformation was confirmed by sequencing to ensure that the vector was empty. 
The empty vector strain of E.coli was then grown using the same procedures previously 
described in section ii. Identical in-cell HMQC NMR experiments were performed and 
analyzed.  
C. Results/discussion 
i. Optimization and visualization of APH in the cell 
The first source of protocol optimization was to reduce the amount of protein leakage from 
the cell. LIVE/DEAD cell assays were performed on cells grown under various conditions 
and the amount of live cells and damaged (termed dead) cells were counted.  As seen in 
Figure 5, cells grown in LB as compared to those grown in minimal M9 media (M9) had 
~10% less total cell death. When cells were grown in LB and then transferred to M9 media 
for 0.5 hours of induction there was 3.3% cell death observed; when the cells were grown 
and induced for 0.5 hours in M9 media there was 17% observed cell death. This indicates 
that there is less cell damage when cells are grown in LB and then transferred to M9 for 
induction. Induction times of 1 hour and 1.5 hours caused cell death to increase to 5% and 
26% respectively. Induction time was the most influential variable in terms of affecting cell 
viability. When cells were grown in LB and transferred to M9 media for a 0.5 hour 
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induction followed by transfer to a deuterated PBS buffer, cell death decreased to 2.3%. 
These conditions were determined to be optimal.  
The second source of protocol optimization was to determine the appropriate method of 
lysing the cells. Keeping in mind the sample size and what was previously shown to 
inactivate APH, several different conditions were tried. Figure 6 shows that lanes 3-12 
exhibit good cell lysis as seen by the presence of several protein bands as well as an 
overexpression of APH which is boxed in at 31 kDa. Addition of lysozyme did not 
significantly increase the amount of cell lysis. The optimal method of lysis was determined 
to be at least 4 freeze-thaw cycles.  
HMQC spectra of whole cells grown and induced under optimal conditions produced a 
spectrum with 9 distinct peaks (Figure 7). The HMQC spectra of the supernatant did not 
contain a significant signal indicating that there was little to no leakage of APH out of the 
cell at this time. The HMQC spectra of the lysate contained an additional 20 peaks, this 
indicates that once released from the crowded environment of the cell, APH is much more 
visible. The lysate, while less crowded, still contains all of the proteins and organelles that 
were once contained in the cell and therefore we do not expect to see a re-establishment of 
the spectra of purified labeled APH.   
In-cell NMR experiments were performed on E.coli BL21 (DES) cells containing an empty 
pET-15b vector as a negative control. In Figure 8, HSQC NMR experiments show that when 
grown under optimal growth and induction conditions there is some inclusion of 15N into 
the cell.  The supernatant does not have visible 15N signal and the lysate shows a 
reappearance of the same 4 peaks. This reappearance indicates that there is inclusion of 
15N into the cell. Compared to the spectra of our in-cell APH, APH has an increased number 
of peaks confirming that we are able to detect, although a bit limited by the lack of varying 
peaks, the labeled APH.  
ii. In-cell structural changes of APH    
LIVE/DEAD cell assays were used to determine the appropriate amount of antibiotic 
(neomycin B, tobramycin or kanamycin A) to add to the whole cell sample (Figure 5). The 
goal was to determine the antibiotic that could be present in high concentrations, without 
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causing more than 5% cell death. In Figure 5, b-d compare amount of antibiotic added to 
the number of live and dead cells that resulted. It was concluded that the addition of 
neomycin B caused less cell death at higher concentrations than either kanamycin A or 
tobramycin. However, these experiments showed that relatively little aminoglycoside could 
be used before inducing large amounts of cell death. 
In Figure 4, HSQC NMR experiments of APH with 150 mg/ml BSA show that in the presence 
of a crowding agent, APH is still highly overlapped and therefore flexible. HSQC NMR 
experiments of the addition of 5 mM neomycin B to APH in the presence of crowding agent 
BSA resulted in a large amount of peak dispersion (Figure 4). BSA interacts with neomycin, 
therefore high concentrations were necessary to ensure APH saturation [45].  The peak 
dispersion indicates that the binding of neomycin B causes a conformational change of APH 
even when in crowding conditions.  
Shown in Figure 7 are spectra of the whole cell, supernatant, lysate and lysate with 
neomycin. The addition of 10 mM neomycin B to the lysate causes shifts in several 
resonances, best seen by the overlay image in Figure 7. These shifts tell us that the binding 
of neomycin B to APH causes a conformational change in the crowded environment of the 
lysate. The mechanism by which aminoglycosides work to kill bacterial cells makes it 
difficult to visualize binding AGMEs in the cell. This was shown to be the case with 
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Figure 4: 1H 15N HSQC NMR spectra of APH complexes. APH in its apo (top), in the presence 
of 150 mg/ml BSA (middle), and in the presence of 150 mg/ml BSA and 5mM neomycin B 
(bottom) are shown. All spectra were taken under similar environmental conditions and 





Figure 5: Results of LIVE/DEAD cell assays, (a.) total cell count for each growth condition 
was normalized to 1000. Green portion represents cells counted as alive, and the red 
portion represents cells counted as damaged or dead. Growing conditions include cells that 
were  grown in LB media and not induced (lane 1), cells grown in M9 media and not 
induced (lane 2), cells grown in LB and transferred to M9 for a 0.5 hour induction (lane 3), 
cells  grown in M9 and induced for 0.5 hours (lane 4), cells grown in LB and transferred to 
M9 for 0.5 hour induction then transferred to PBS buffer (lane 5), cells grown in LB and 
transferred to M9 for 1 hour of induction (lane 6), and cells grown in LB and transferred to 
M9 for 1.5 hours of induction. (b-d) LIVE/DEAD cell assays of cells grown and induced for 
0.5 hours under optimal growth conditions. Cells were then exposed to various amounts of 
an aminoglycoside antibiotic: kanamycin A (b), neomycin B (c) and tobramycin (d).  After 
45 minutes of incubation cells were stained and fluorescence was viewed. Live (light grey) 







Figure 6: SDS gel picture of proteins extracted using  various cell lysis 
techniques: purified APH (lane 1), cell supernatant prior to lysis (lane 2), 
freeze thaw 3x with heated lysozyme (lane 3), freeze thaw 3x  (lane 4), freeze 
thaw 3x with unheated lysozyme (lane 5), freeze thaw 3x with preheated 
lysozyme (lane 6), freeze thaw 4x (lane 7), freeze thaw 4x with heated 
lysozyme (lane 8), freeze thaw 4x with preheated lysozyme (lane 9), freeze 
thaw 5x (lane 10), freeze thaw with unheated lysozyme (lane 11), and freeze 
thaw 5x with preheated lysozyme (lane 12). The black box depicts the location 
of APH on the gel in lane 1, and in lanes 3-12.  
  
 







Figure 7: 1H- 15N HMQC NMR spectra of in-cell experiments. APH located in the cell (upper 
left) is purple, the supernatant (upper right) is green, the lysate (middle left) is blue, lysate 
plus 10 mM neomycin (middle right) is red and an overlay of spectra with lysate (blue) and 
lysate with 10 mM neomycin (red) is in the lower panel. All spectra were taken under 
similar experimental conditions and shown to matching contour levels. 
Whole cell  
Lysate + 10mM 
neomycin B 
Lysate 
Overlay of lysate 







Figure 8: 1H- 15N HMQC NMR spectra of e.coli (BL21) cells containing an empty pET-15b 
vector. Whole cell (top) is shown in green, supernatant (middle) is shown in red, and lysate 
(bottom) is shown in blue. All spectra were taken under similar experimental conditions 












Chapter III: APH flexibility allows binding to structurally 
rigid aminoglycosides 
A. Background 
i. Introduction to acetyltransferases(3)-IIa and IIIb 
Acetyltransferases AAC(3)-IIa and AAC(3)-IIIb will be referred to as AAC-IIa and AAC-IIIb 
unless specificity is required. APH is a highly promiscuous AGME with a known flexible 
nature. Aminoglycoside acetyltransferases are another family of AGMEs, and among them 
they have range of substrate profiles as well as intrinsic disorder.  Two well-studied AAC’s: 
AAC-IIa and AAC-IIIb catalyze the transfer of an acetyl group from coenzyme A (CoASH) 
onto the 3-N position on the central 2-DOS ring of aminoglycoside antibiotics [46]. 
Modification at this site causes a significant loss of antibiotic effectiveness. AAC-IIa, like 
APH, is highly dynamic in solution and displays properties of being intrinsically disordered 
in the absence of aminoglycoside substrate [2]. Upon binding of aminoglycoside, AAC-IIa 
adapts a well-defined structure (Figure 9). Unlike APH, AAC-IIa has a limited substrate 
profile, selecting aminoglycosides almost exclusively from the kanamycin family.  
 AAC-IIIb has a large substrate profile and is able to confer resistance to antibiotics from 
both the kanamycin and neomycin families; AAC-IIIb does not have structural flexibility in 
the absence of aminoglycosides. The binding of CoASH to AAC-IIIb causes increased 
flexibility of the long loop in the antibiotic binding domain [47].  The presence of CoASH 
causes an increased association between the enzyme and antibiotic for both AAC-IIa and 
AAC-IIIb [2]. AAC-IIa shares approximately 35% amino acid sequence identity and 
approximately 39% sequence similarity with AAC-IIIb [2]. There are no crystal structures 
available for either of these proteins, but structure models show that they are very similar 
and superimpose to 1.43 Å over the entire protein [2]. The source of differences in their 
substrate promiscuity is still under investigation.  
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ii. Binding of sisomicin to acetyltransferases(3)-IIa and IIIb 
Sisomicin is an aminoglycoside first isolated in 1970, and is active against gram-positive 
bacteria [48].   Sisomicin is considered part of the gentamicin family, an aminoglycoside 
family with a 4,6-disubstituted central 2-DOS ring (Figure 1) [49]. Sisomicin contains an 
unsaturated diamino sugar ring which is unique to it and netilmicin. Sisomicin contains 2 
methyl groups on its double primed ring, which may influence its ability to bind various 
AGMEs. Netilmicin is identical to sisomicin except for an additional methyl group on its 
unprimed central ring (Figure 1). Kinetic studies revealed that sisomicin is acetylated at a 
faster rate by AAC-IIIb but has a lower Km value with AAC-IIa [2]. Among the 
aminoglycosides tested with AAC-IIa, sisomicin has the lowest Km value. ITC experiments 
reveal that association of sisomicin to AAC-IIa is enthalpically favored (-49 kcal/mol) and 
entropically disfavored. When sisomicin associates to the binary AAC-IIa-CoASH complex, 
the aminoglycoside affinity increases 15-50 fold and enthalpy is less favored (-9.7 
kcal/mol) [2]. Binding of sisomicin to AAC-IIIb is associated with a favorable enthalpy. For 
both enzymes, the addition of CoASH causes sisomicin to bind with higher affinity, seen by 
a decrease in their respective KD values [2]. The formation of ternary complexes with 
sisomicin causes an increase in favorable enthalpy with AAC-IIIb but a decrease in 
favorable enthalpy with AAC-IIa. Changes in enthalpy are compensated by changes in 
entropy to result in relatively unchanged changes in free energy [2].  
Mentioned previously, NMR experiments show that the spectra of apo-AAC-IIa are highly 
overlapped, indicative of an intrinsically disordered protein. Binding of tobramycin to AAC-
IIa causes the complex to gain structure. Binding of sisomicin to AAC-IIa also causes a gain 
in structure, however when compared to the tobramycin binary complex, there is less peak 
dispersion indicating that the sisomicin binary complex retains some flexibility (Figure 9). 
The addition of tobramycin to the AAC-IIa-CoASH complex, shown in Figure 9, reveals that 
formation of the ternary complex is very similar to that of the tobramycin binary complex. 
Addition of sisomicin to form the ternary complex causes a larger change in peak 
dispersion. This indicates that CoASH is required by the AAC-IIa-sisomicin complex to 
achieve similarly well-defined structural features similar to that observed with the binary 
AAC-IIa-tobramycin and ternary AAC-IIa-CoASH-tobramycin complexes [2].  AAC-IIa may 
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be inhibited from entering a more structured form when only sisomicin binds because of 
the rigid diamino sugar ring. To investigate the ability of flexible proteins to overcome 
structural differences in substrates, the binding interactions of APH are examined with 
sisomicin and netilmicin.          
iii. Formation of differing ternary complexes dependent upon order of addition 
AAC-IIIb with its two substrates, CoASH and aminoglycosides, forms a ternary complex. 
However, adding the substrates, neomycin B and paromomycin, in varying orders results in 
ternary complexes that are not identical to one another (Norris, unpublished). In the first 
pathway to form the ternary complex the binding order is AAC-IIIb, neomycin then CoASH, 
in the second pathway the order of binding is AAC-IIIb, CoASH and then neomycin.  
However, Hess’s law is still obeyed in the formation of the ternary complex in both forms 
[50]. Hess’s law states that “the enthalpy change for any sequence of reactions that sum to 
the same overall reaction is identical” [51]. Based on Hess’s law, the change in enthalpy 
found by adding the substrates in differing orders should result in the same total change in 
enthalpy if the same ternary product is formed. Using differential scanning calorimetry 
(DSC) they demonstrated that the melting temperature of ternary complex AAC-CoASH-
neomycin was 2.3 °C higher than the melting temperature of ternary complex AAC-
neomycin-CoASH. There are also differences in the hydrodynamic radius, final NMR 
spectra, and solvent protection of the ternary complexes dependent upon the order of 
addition (Norris et al., manuscript under review). Together the data suggest that the order 
of addition plays a large role in the final ternary complex that is formed with AAC-IIIb. This 
is the first time that the order of addition has been investigated with AGMEs. Similar 
differences were observed with AAC-IIa and sisomicin (Norris, unpublished). Here the 






Figure 9: NMR spectra comparing the peak dispersion of binary (top) and 
ternary (bottom) complexes of sisomicin (red) and tobramycin (black) with 




i. Chemicals and Reagents 
99% D2O and 15N-enriched salts were purchased from Cambridge Isotope Laboratories 
(Andover, MA).  Thrombin was purchased from Enzyme Research Laboratories (South 
Bend, IN), IPTG from Inalco Spa (Milan, Italy) and the high performance Ni Sepharose resin 
used for APH purification was purchased from Amersham biosciences (Piscataway, NJ). 
Ion-exchange matrix Macro Q is from Bio-Rad laboratories (Hercules, CA). Aminoglycoside, 
and all other chemicals and reagents were purchases in the highest purity available from 
Sigma-Aldrich or Fisher. Desulfated Aminoglycoside were used for all kinetic and 
thermodynamic studies, concentrations were determined by activity assays previously 
described [52].     
ii. Growth and purification of APH 
Following a previously established protocol, BL21 E.coli cells with APH containing pET-15b 
expression vector were grown at 37 °C with agitation to an OD600 of ~0.8 in either LB (for 
unlabeled APH) or M9 minimal media containing 15NH4Cl (for 15N labeled APH) [30, 36]. LB 
contained 0.1 mg/ml AMP. APH expression was induced by the addition of 1 mM of IPTG.  
Cells were harvested by centrifugation after 4 hours, and stored at -80 °C for up to 12 
months.  For purification, cells were suspended in lysis buffer (100 mM NaCl, 20 mM 
imidazole, 200 µM PMSF, and 50 mM Tris-HCl pH 7.4 at 4 °C). Cells were lysed by three 
passes through a French press and cell debris pelleted by centrifugation. APH was purified 
from the crude lysate by nickel affinity chromatography. Thrombin was used to 
proteolytically remove the Histag from APH.  Separation of cleaved APH was achieved 
through nickel affinity chromatography, and separation from excess thrombin by ion-
exchange chromatography. The ratio of UV absorbance at 280 nm and 260 nm confirmed 
that the protein was freed from nucleic acids. Purified APH was dialyzed extensively in 
appropriate buffer at 50 mM (pH 7.4) at 4 °C, 100 mM NaCl, and 2 mM TCEP-HCl, then 
stored at 4 °C for up to one week or frozen immediately using liquid nitrogen and stored at 
-80 °C. Final concentrations of protein were determined at absorbance of 280 nm using an 
extinction coefficient value of 1.54. 
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iii. Steady-state kinetics 
Sisomicin does not have a hydroxyl located on its C-3 primed ring, therefore APH is unable 
to chemically modify sisomicin. Kinetic parameters for the inhibition activity of sisomicin 
were determined by using a continuous assay previously described [36]. Phosphorylation 
of aminoglycoside antibiotics is monitored by a coupled reaction of the ADP generated 
from phosphorylation of the aminoglycoside to the oxidation of NADH using the enzymes 
pyruvate kinase and lactate dehydrogenase. The oxidation of NADH is monitored at 340 nm 
using a Cary-Win UV-vis spectrophotometer (Varian, Palo Alto, CA). The spectrometer was 
blanked with 985 µl deionized water, and the NADH stock was tested by adding 15 µl to 
water and observing the change in absorbance. Next, 970 µl of assay mix (50 mM Tris pH 
7.4, 50 mM KCl, 1 mM ATP, 1.5 mM MgCl2, and 2 mM phosphoenolpyruvate trisodium salt 
at 25 °C) is added to appropriate amounts of sisomicin and kanamycin A as well as 150 µM 
NADH and 0.02 mg/ml pyruvate kinase/lactate dehydrogenase enzyme solution. The 
reaction was then initiated by the addition of 10 µl of 100 µM purified APH.  The reactions 
followed Michaelis-Menten type kinetics where sisomicin is a competitive inhibitor. The 
specific activity (micromoles per second per milligram) was plotted versus substrate 
concentration and fitted to the equation below in order to determine the Ki of sisomicin, 




where ν=the initial velocity, and Km is the Michaelis constant.  
iv. Isothermal titration calorimetry 
ITC experiments were performed at 25 °C using a VP-ITC macrocalorimeter from Microcal, 
Inc. (Northampton, MA). APH concentrations were kept between 20-30 µM to maintain the 
c-value, a parameter obtained by multiplying the association constant and the total 
concentration of the ligand binding site, was kept between 1 and 100. Measurements were 
carried out in 50 mM Tris-HCl, PIPES, HEPES, or ACES buffers which also contained 100 
mM NaCl and 2 mM TCEP-HCl at a pH of 7.4. Enzyme preparations include a final step of 
dialysis into one of the listed buffers. Ligand solutions were prepared with the same 
dialysate as was used for the enzyme. The pH was checked for both solutions and kept 
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within 0.05 units of each other, samples were then degassed under vacuum for 10 minutes 
before being appropriately loaded into the VP-ITC macrocalorimeter.  Titrations of 
substrate into enzyme solution consisted of 29 injections of 10 µl, separated by 240 
seconds with a cell stirring speed of 300 rpm. 
Binary titrations included the titration of aminoglycoside, or AMPPCP solution into enzyme 
solution. Aminoglycoside concentrations ranged from 0.25-1 mM, and the AMPPCP 
concentration was 2.25 mM.  Ternary titrations included either the titration of 
aminoglycoside into the enzyme-Mg-AMPPCP complex, or the titration of AMPPCP into 
enzyme-aminoglycoside-Mg complex. In ternary experiments where aminoglycoside was 
titrated in, the Mg-AMPPCP concentration was kept constant at 1.25 mM in both solutions. 
In ternary experiments where AMPPCP was titrated in, the antibiotic concentration was 
kept constant at either 0.5 or 1 mM for either sisomicin or netilmicin respectively, and Mg 
was at saturating levels of 1.25 mM. By keeping all of the additional substrates at saturating 
levels in both solutions the heat associated with binding of either aminoglycoside or 
AMPPCP respectively were measured exclusively. Enzymatic activity was periodically 
checked before and after titrations. Sedphat software as well as nitpic software were used 
to fit the data. Isotherms depicted were created using nitpic software. Binding of an 
aminoglycoside to APH causes a well-documented shift in the pKa values of several 
functional groups, therefore each binding experiment was performed in at least 3 of the 
following buffers: Tris-HCl, ACES, HEPES, or PIPES. The buffers have varying heats of 
ionization (∆Hion), 11.4, 7.3, 4.87, and 2.7 respectively [53]. The observed enthalpy (∆Hobs ) 
contains contributions from various sources as seen by the equation [54]: 
                [                 ]         
In the equation above, ∆Hint is the intrinsic enthalpy of binding, and ∆n is the net 
protonation. The portion of the equation in brackets represents the heat of ionization from 
the buffer and the protein (∆Henz) which maintains the pH. In the presence of high 
concentrations of salt (i.e., 100 mM NaCl) the heat of binding of buffer to enzyme (∆Hbind) is 
assumed to be zero [54].   Therefore by performing each binding experiment in 3 buffers 
with different ∆Hion, the ∆Hint and ∆n can be determined using the equation:  
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v. Differential scanning calorimetry 
DSC experiments were performed in PIPES buffer on a VP-DSC Microcalorimeter from 
MicroCal. It was previously established that APH is able to refold after heat denaturation. 
The melting transition data was recorded from 10 °C until 75 °C for just the buffer, apo 
APH, binary APH-Sisomicin, ternary complexes where sisomicin was added to APH-Mg-
AMPPCP complex or AMPPCP was added to APH-sisomicin-Mg complex and buffer with Mg, 
sisomicin and AMPPCP. PIPES buffer was used in the reference cell. All samples were 
degassed for 15 minutes prior to injection and contained one to three of the following: 50 
µM purified APH dialyzed in PIPES buffer (50 mM PIPES, 100 mMNaCl, 2 mM T-CEP and pH 
of 7.4), 1.25 mM MgCl2, 1.25 mM AMPPCP, 0.5 mM sisomicin, with the final volume made up 
of PIPES buffer. Origin software was used to analyze the data with a non-2-state model for 
fitting. Baselines were not stable enough to reliably calculate the change in heat capacity.     
vi. Nuclear magnetic resonance  
NMR samples used contained 150 µM purified 15N labeled APH protein, in 50 mM MOPS 
buffer, 2 mM TCEP-HCl, 100 mM NaCl, and 7% D2O, pH 7.4. Experiments included using 
samples of apo APH, the addition of 0.5mM desulfated sisomicin, and finally the addition of 
1.25 mM MgCl2 and 1.25 mM AMPPCP. Apo APH sample was transferred to a Shigemi tube 
(Allison Park, PA) with a total volume of 350 µl. HSQC spectra were obtained on a Varian 
Inova 600 MHz triple resonance spectrometer at 25 °C at the University of Tennessee. 
HSQC experiment parameters were optimized, and included a delay of 1.5 seconds between 
scans, pulse width of 8.05 µs, 64 transients, and a spectral width of 8012. The binary and 
ternary samples were prepared by titration of appropriate amount of substrate into apo 
APH sample, HSQC parameters were kept the same. Spectra were processed with nmrDraw 
and exported to Sparky for analysis and display [43, 44]. Adobe Photoshop software was 
used to invert and change the color of the images. APH protein model 1L8T from the 
protein data bank was used to highlight shifted amino acids in Molecular Operating 
Environment (MOE) at The University of Tennessee. The model is from crystal structure 




i. Kinetic interactions of APH with sisomicin 
Most aminoglycoside substrates demonstrate substrate inhibition as they compete for the 
same binding site and sisomicin is not an exception [2, 36]. However because sisomicin 
does not have a hydroxyl group on its 3′ carbon, it is unable to be chemically modified by 
APH. As expected, it is a competitive inhibitor with respect to aminoglycosides and the 
determined Ki value of sisomicin is 0.203 ± 0.089 mM. Sisomicin has an inhibition constant 
(Ki) of >700 µM and ~1000 µM with AAC-IIIb and AAC-IIa respectively. It is important to 
note that Ki and Km values are not correlated to one another. For instance, a substrate with 
a low Km value need not have a low Ki value. Therefore, no further conclusions can be 
drawn from this value.    
ii. Thermodynamic interactions of APH with sisomicin and netilmicin  
Binary and ternary thermodynamic interactions of APH with kanamycin A, kanamycin B, 
tobramycin, amikacin, ribostamycin, neomycin B, paromomycin I, and lividomycin A were 
previously published in 2004 [30]. The previous ITC experiments were done at 37 °C, 
contained 50-100 µM APH, 0.75-3 mM aminoglycoside concentration and buffers contained 
100 mM KCl instead of 100 mM NaCl. However, these changes should not affect the 
observed trends [30]. Furthermore, binary APH ITC experiments were performed under 
currently used conditions with antibiotics: kanamycin A, kanamycin B, neomycin B and 
ribostamycin (Wright, unpublished data). At 25 °C, antibiotics have similar KD values to 
previously published KD values, less favorable enthalpy (ranging from 3 to 29.8 kcal/mol 
less favorable due to large heat capacity change observed with this enzyme), and a 
correlating increase in favorable entropy. Binary binding parameters for APH complexes 
with sisomicin, netilmicin and AMPPCP are found in Table 1. Binary binding of APH with 
sisomicin had a KD value similar to that of kanamycin A. Kanamycin B, neomycin B, 
paromomycin I, lividomycin A, ribostamycin and tobramycin all bind to APH with stronger 
affinities than sisomicin and netilmicin [30]. However, both sisomicin and netilmicin bind 
with stronger affinities than amikacin, which has a bulky group attached to the N-1 of its 2-
DOS ring. The neamine portion of the antibiotic has been shown to be important for 
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binding; therefore large groups found on the first two rings may be more inhibitory than 
the unsaturated prime diamino ring found on sisomicin and netilmicin. Netilmicin has a KD 
value approximately two fold higher than that of sisomicin. This difference can be 
attributed to the additional methyl group located on netilmicin in the same location that 
amikacin has its bulky group (Figure 1). This methyl group is predicted to give netilmicin 
an increased hydrophobic property. 
Previous ternary experiments performed in 2004 with APH included changes already 
mentioned as well as the use of CaCl2 and ATP instead of MgCl2 and AMPPCP [30]. Ternary 
parameters determined by ITC are found in Table 2. The KD value of sisomicin to the APH-
Mg-AMPPCP complex showed little change from binary KD value, similar to previous results 
where the addition of antibiotic to APH-Ca-ATP complex remained similar to the binary KD, 
or slightly decreased [30]. This is unlike what is seen with enzyme AAC-IIIb, where the 
addition of co-substrate causes a great increase in affinity of the antibiotic for the enzyme 
complex [46]. Addition of co-substrate has been shown to increase affinity of 
aminoglycoside for enzymes, APH, AAC-IIIb, AAC-IIa, ANT(2″)-Ia, and AAC(6′)-Iy [2, 30, 49, 
55]. Sisomicin follows this trend seen by its general lower KD value when binding the APH-
MgAMPPCP complex, whereas netilmicin did not.   
Interestingly, binding of netilmicin or sisomicin to APH is associated with relatively less 
favored enthalpy, as well as the most favorable entropy seen in literature of APH relative to 
other aminoglycosides [30].  Formation of the netilmicin binary complex had the most 
unfavorable intrinsic enthalpy, and the sisomicin binary complex was only slightly more 
favorable: -7.6 and -10.3 kcal/mol, respectively (Table 1). Binary experiments, APH-
sisomicin, performed in Tris-HCl, and HEPES buffers had a favorable entropy (18 and 5.8 
cal/K respectively) associated with the binding of sisomicin to APH (Figure 10). Binary 
Netilmicin ITC experiments had a favorable entropic contribution in all buffers (Figure 11). 
Netilmicin has the most favorable entropy associated with binary complex formation of an 
aminoglycoside with APH as reported so far in literature. Netilmicin binary complex 
formation in Tris-HCl buffer was endothermic because of proton contribution of the buffer, 
and low enthalpic contributions of the reaction (Figure 11). Favorable entropy is often a 
reflection of increased disorder caused by the release of water [31]. There is compensation 
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that occurs with enthalpy and entropy values to yield a relatively unchanged favorable ∆G. 
The additional methyl group on netilmicin seems to also play a role in the thermodynamic 
contributions of binding, further emphasizing trends seen with sisomicin. The hydrophobic 
qualities of these substrates cause an increase in favorable entropic contributions as well 
as a correlated decrease in favorable enthalpic contributions.  This indicates that there is 
interaction of the hydrophobic groups with APH’s active site, as was seen with AAC(6′)-Iy 
[55].  APH is able to interact with the double primed ring region of the antibiotics and 
methyl groups found here, which affects the order of water molecules and various global 
hydrogen bonds formed.        
Formation of the binary APH complexes with sisomicin and netilmicin are both associated 
with a positive net protonation of the complex, which may indicate an upshift in pKa values 
for several functional groups in both ligand and enzyme (Figure 12) [54, 56]. Amikacin and 
ribostamycin are the only antibiotics recorded to cause a net deprotonation when binding 
APH [30].  There is also positive net protonation associated with the addition of sisomicin 
or netilmicin to the APH-Mg-AMPPCP complex.  This follows the general trend seen from 
previous experiments done with other antibiotics [30]. Binding of aminoglycoside 
antibiotic to the binary APH-metal-ATP complex has been shown to always have a positive 
net protonation.   
When comparing changes in thermodynamics between the binding of antibiotic to APH 
(binary) and the binding of antibiotic to APH-metal-ATP complex (ternary) typically the 
ternary complex has a less favorable enthalpy (10-20 kcal/mol) and an increased favorable 
entropy [30].  The binding of amikacin is the only antibiotic that has been previously found 
to cause an increased favorable enthalpy with the formation of the ternary complex [30]. 
Binding of sisomicin to form the ternary complex had a very slight increase in favorable 
intrinsic enthalpy (0.2 kcal/mol), whereas binding of netilmicin to form the ternary 
complex decreased the favorable enthalpy by 1 kcal/mol (Table 2). The reasons behind this 
have yet to be elucidated at this time. Sisomicin and netilmicin bind fairly tightly with APH 
yet they do not follow the thermodynamic trends previously seen with this enzyme. The 
only other antibiotic to deviate from the general thermodynamic trends, amikacin, has the 
lowest binding affinity to APH, approximately 20 times lower than sisomicin.  
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Typical carbohydrate-protein interactions are characterized by a favorable enthalpy and 
unfavorable entropy [57]. Expanding our comparison to other AGMEs, binary binding of 
sisomicin to AAC-IIIb also yields a small favorable heat contribution made by enthalpy and 
has a favorable entropy [2]. Binding of sisomicin to AAC-IIa had a highly favorable 
enthalpic contribution and unfavorable entropic contribution similar to data of binding of 
other antibiotics to AAC(3)-IIa. Binary binding of netilmicin with AAC(6′)-Iy also has a 
favorable entropy, however binding of sisomicin did not [55]. The only other antibiotics 
with documented favorable entropic contribution are kanamycin A binding to either AAC-
IIa or IIIb, and amikacin to AAC(6′)-Iy [2, 46, 55]. The reasons behind this similarity are still 
unknown at this time. Binding of aminoglycosides to AGMEs typically results in favorable 
enthalpy and unfavorable entropy, additionally seen with AAC(3)-IV, ANT(4′) and ANT(2″) 
[49, 58, 59].  
iii. Thermodynamics of the ternary complex formation are not dependent upon the order 
of addition 
The formation of ternary complex APH-siso-Mg-AMPPCP is associated with a favorable 
intrinsic enthalpy, and unfavorable entropy (Table 2). The binary complex, APH-AMPPCP, 
had a favorable enthalpy as well as favorable entropy, consistent with APH binding to other 
ATP analogs (Table 1) [60]. According to Hess’s law the total enthalpy change of one 
pathway should be the same as another if the same final product is formed. Therefore by 
adding the enthalpies of binary APH-siso complex and ternary APH-siso-Mg-AMPPCP 
complex and comparing the total to the total enthalpy found by the adding enthalpy of 
binary APH-AMPPCP complex to ternary APH-Mg-AMPPCP complex, inferences can be 
made about the final complex formation dependent upon the order of substrate addition.  
                                                                                                                
For ITC, experiments done in Tris-HCl buffer, the total changes in enthalpy for each 
pathway were within error of each other. This indicates that for APH, the order of binding 
does not change the thermodynamic properties of the final ternary complex, and therefore 
follows Hess’s law. 
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iv. Differential scanning calorimetry of APH complexes 
As seen in Figure 13, the melting temperature of APH complexes occurred as a single 
denaturation event (single peak). The Tm of the apo APH was calculated to be 47.5 °C. The 
Tm of the binary APH-siso complex was 54.2 °C. When compared to previous DSC 
experiments of APH bound to various well known aminoglycosides substrates, the melting 
temperature of APH-siso is comparable with that of APH-KanA (Wright, unpublished). This 
suggests that APH is able to bind sisomicin with a formation of structure similar to that 
seen with other aminoglycosides. The Tm of ternary APH-siso-Mg-AMPPCP complex and 
ternary APH-Mg-AMPPCP-siso complexes were 55.2 °C and 54.9 °C respectively. The 
melting temperatures of both ternary complexes are within 0.3 °C of each other; this 
indicates that the complex formed by the addition of sisomicin to the APH-Mg-AMPPCP 
complex is very similar if not identical to the complex formed by the addition of AMPPCP to 
the APH-sisomicin-Mg complex.  
The addition of sisomicin to APH resulted in a higher Tm when compared to the apo APH 
complex, this is similar to what was seen with other aminoglycosides. This is unlike AAC-IIa 
which adopts a more flexible conformation to accommodate the methyl groups as well as 
the unsaturated primed diamino sugar ring of sisomicin, and had a lower Tm than when 
bound to other aminoglycosides.  
v. Nuclear magnetic resonance of APH-siso complex 
It was previously shown that even after the binding of sisomicin to flexible protein AAC-IIa, 
AAC-IIa retained some of its flexibility as compared to its binding of tobramycin [2]. Shown 
in Figure 14 is the binding of sisomicin to APH, binding results in a peak dispersion that is 
relatively similar to APH bound to tobramycin (Figure 3). This indicates that the APH 
conformation formed by sisomicin binding to APH is not drastically different than that of 
the complex formed by tobramycin binding to APH. The NMR resonances for tobramycin 
bound APH were previously assigned and published, therefore chemical shifts of specific 
amino acids can be determined by spectral comparisons [29]. Figure 15 depicts the amino 
acids that show significant changes in their chemical shifts. Comparison between two-
dimensional HSQC spectra of APH-tobramycin complex and APH-sisomicin complex 
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revealed that there was a significant shift in 23 amino acid assigned resonances. Notably, 
there was a shift in Glu160 and Asp190. Both amino acids have been shown to interact with 
the aminoglycoside substrate by x-ray crystallography[27]. There was a noticeable shift in 
several amino acids in the flexible binding loop that is predicted to be intrinsically 
disordered: Ala141, Asp144, Asp153, Asp155, Cys156, and Glu160; as well as several other 
amino acids located in and around the aminoglycoside binding pocket. Out of the 23 amino 
acids that shifted their resonance, 8 were negatively charged, and 7 were hydrophobic. The 
fact that amino acid residues showed significant shifts distributed all over the protein, 
including remote sites, is again consistent with the role of flexibility of APH to bind 
structurally different aminoglycosides. 
Overall the NMR data indicates that the binary APH-sisomicin complex has gained a 
significant amount of structure as compared to the apo APH complex. The retained 
flexibility that was observed with AAC-IIa bound to sisomicin is not observed with APH 
bound to sisomicin. Therefore APH is able to compensate for the additional restrictions 
presented by sisomicin. The flexible nature of APH is better able to overcome structural 
differences in substrates to form additional interactions with the substrate. The flexible 


















      Table 1: Thermodynamic parameters for Aminoglycoside binding (binary complex)a 










sisomicin Tris-HCl 4.7 ± 2.2 -1.9 ± 0.6 -10.4 ± 0.8 -5.4 ± 0.7 -7.3 ± 0.2 0.7 ± 0.1 
HEPES 1.6 ± 0.9 -6.2 ± 0.1 -1.7 ± 0.2 -7.9 ± 0.05 
PIPES 4.2 ± 1.2 -8.8 ± 0.1 1.5 ± 0.1 -7.3 ± 0.02 
netilmicin Tris-HCl 7.1 ± 0.7 1.6 ± 0.04 -7.6 ± 0.8 -8.6 ± 0.01 -7.02 ± 0.05 0.8 ± 0.1 
ACES 7.4 ± 1.9 -1.3 ± 0.08 -5.7 ± 0.2 -7.0 ± 0.1 
HEPES 6.9 ± 0.9 -4.5 ± 0.1 -2.6 ± 0.2 -7.04 ± 0.2 
PIPES 9.1 ± 0.3 -5.1 ± 0.04 -1.8 ± 0.06 -6.9 ± 0.02 
AMPPCP Tris-HCl 12.2 ± 8.6 -4.2 ± 2.2 ND -2.5 ± 2.6 -6.7 ± 0.3 ND 
a Given errors were calculated by fits to sedphat critical chi-square for error surface projections. b Errors for 
intrinsic enthalpy(ΔHint) and net protonation (Δn) are derived from the deviation from linearity of ΔHobs vs 







      Table 2: Thermodynamic parameters for Aminoglycoside binding (ternary complex)a 










sisomicin Tris-HCl 4.3 ± 0.6 -5.0 ± 0.6 -10.5 ± 0.5 -2.3 ± 0.4 -7.3 ± 0.1 0.5 ± 0.07 
HEPES 3.2 ± 0.3 -7.8 ± 0.2 0.3 ± 0.3 -7.5 ± 0.05 
PIPES 4.2 ± 0.08 -9.5 ± 0.05 2.2 ± 0.05 -7.3 ± 0.01 
netilmicin ACES 27.5 ± 18.8 -3.0 ± 0.7 -6.5 ± 1.9 -3.0 ± 1.2 -6.2 ± 0.5 0.4 ± 0.4 
HEPES 11.0 ± 2.5 -5.4 ± 0.3 -1.4 ± 0.4 -6.8 ± 0.1 
PIPES 12.3 ± 2.8 -4.9 ± 0.05 -1.8 ± 0.08 -6.7 ± 0.02 
AMPPCPc Tris-HCl 91.5 ± 16.8 -11.8 ± 1.3 -6.4 ± 0.5 6.3 ± 1.1 -5.5 ± 0.07 -0.5 ± 0.06 
HEPES 69.3 ± 3.9 -9.0 ± 1.3 3.3 ± 1.4 -5.7 ± 0.07 
PIPES 86.6 ± 14.2 -7.4 ± 0.6 1.9 ± 0.7 -5.5 ± 0.05 
a Given errors were calculated by fits to sedphat critical chi-square for error surface projections, ternary 
experiments where the aminoglycoside was titrated into APH-Mg-AMPPCP complex. b Errors for intrinsic 
enthalpy(ΔHint) and net protonation (Δn) are derived from the deviation from linearity of ΔHobs vs ΔHion 




Figure 10: Typical thermogram (top) and isotherm (bottom) for titration of sisomicin into 
APH in buffers PIPES (purple), HEPES (blue) and Tris-HCl (black).  Time integration of the 
thermal power yields the heat of injection. In the isotherms, data points are shown with a 









Figure 11: Typical thermogram (top) and isotherm (bottom) for titration of netilmicin into 
APH in buffers PIPES (purple), HEPES (blue), ACES (green) and Tris-HCl (black)  Time 
integration of the thermal power yields the heat of injection. In the isotherms, data points 





Figure 12 : Determination of the intrinsic enthalpy of binding. The observed enthalpy 
determined in different buffers is plotted vs the heat of ionization of the buffer. Depicted are 
binary APH-sisomcin (blue), ternary APH-Mg-AMPPCP-sisomcin (red), binary APH-
netilmicin (green), and ternary APH-Mg-AMPPCP-netilmicin (purple). R values for the linear 








Figure 13: DSC traces of APH complexes apo (red), binary APH-sisomicin 
(green), ternary APH-Mg-AMPPCP-sisomicin (black), and ternary APH-





apo APH APH + sisomicin 
Figure 14: 1H-15N HSQC NMR spectra comparing the peak dispersion of apo APH( 
blue) top left, and binary APH-sisomicin (red) top right.  Overlay images of apo 
APH( blue) with binary APH-sisomicin (red)  on the  bottom left. Overlay spectra 
of binary APH-sisomicin (red) with ternary APH-sisomicin-Mg-AMPPCP (green) 
on bottom right. All spectra were taken under similar experimental conditions 
and shown to matching contour levels. 





Figure 15: Structure model of APH bound to ADP (green), two Magnesium ions (orange), 
and kanamycin B (purple).  Highlighted in red are the amino acids  that showed 
significant shift in location on the spectra upon APH binding to sisomicin as compared to 
resonances identified in the binary APH-tobramycin spectra.   
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Chapter IV: Conclusion and future studies 
Exploring the interactions of enzyme APH with its numerous aminoglycoside substrates 
will provide insight into carbohydrate-protein interactions as well as the discovery of 
drugs that target these enzymes. By examining the dynamics of APH in the cell, we were 
able to conclude that the flexible nature of APH that has previously been shown in vitro is 
expected to be true in vivo. Therefore the characteristics attributed to APH’s flexibility are 
expected to present in vivo as well as in vitro. This makes the research previously done with 
APH and its various substrates even more relevant to clinical application.  
It was shown here that in-cell NMR can be used to visualize dynamic protein, APH, in the 
cell. In vitro experiments with BSA showed that APH retains much of its flexibility in 
crowded environments and the addition of neomycin B causes a gain in global structure. 
This change in structure was also visualized in NMR spectrum of APH in the lysate.  When 
neomycin B was added to the lysate sample the spectra changed, indicating a change in 
protein structure. One of the goals for this project was to visualize a change in the structure 
of APH associated with the binding of an aminoglycoside in vivo. However, practical 
limitations prevented the visualization of structural changes associated with the binding of 
neomycin to APH in the cell. High concentrations of neomycin caused increased amounts of 
cell death, which then allowed for cell leakage of proteins from the cell. At lower 
concentrations of neomycin we were not confident that a significant portion of APH was 
bound to neomycin in the cell. However, we are confident that neomycin induces structural 
changes in the cell as this was visualized in both the cell lysate and in the presence of BSA 
where the protein concentrations were high.  
Future directions for in-cell NMR analysis of in vivo structural changes of APH includes 
finding a substrate that is readily imported into the cell but does not cause cell death and 
the optimization of  the induction process or cell line to allow for increased induction time 
or exposure to aminoglycosides without high amounts of cell death or leakage. In-cell NMR 
could also be used to compare structured and flexible apo enzymes AAC-IIIb and AAC-IIa in 
the cell. This comparison would allow look at two relatively similar enzymes, and 
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determine the differences in spectra of flexible AGMEs and structured AGMEs. This 
comparison would also provide insight into the natural state of these two enzymes, for 
example, if AAC-IIIb is typically found bound to CoASH in the cell, then it may be more 
flexible in vivo than it has been shown to be in vitro.   
There are relatively few published thermodynamic studies with AGMEs; APH is 
thermodynamically, one of the well characterized AGMEs. This allows for comparisons 
between the bindings of its various aminoglycoside substrates. The promiscuity of APH is 
largely attributed to its flexibility which accommodates a large number of aminoglycoside 
chemical structures. The binding of APH with sisomicin or netilmicin is yet another 
example of APH’s ability to accommodate for structural diversity in its substrates. AAC-IIa 
is unable to completely accommodate for the additional methyl groups and unsaturated 
sugar ring of sisomicin.   It was shown here that binding of sisomicin to APH, unlike AAC-IIa 
where part of the enzyme remains unstructured, results in a well-structured complex; 
similar in conformation to complexes formed with APH and other aminoglycosides. DSC 
data showed that the melting temperature of binary complex APH-sisomicin was also 
similar to when APH is bound to other members of the kanamycin group aminoglycosides. 
The AAC-IIa-sisomicin complex showed a lower melting temperature than complexes of 
other kanamycins with this enzyme. DSC data also highlighted another difference between 
these two highly flexible enzymes; APH and its complexes with ligands were all reversible 
transitions while AAC-IIa denaturation was irreversible.  Unlike AAC-IIIb, the order of 
addition of substrates did not yield ternary APH complexes with different dynamic 
properties.  
Interestingly, the binding of netilmicin to APH highlighted an interesting effect of altered 
pKas of titratable groups on the observed binding enthalpy. When binding netilmicin to 
APH is tested in Tris-HCl, the reaction appeared to be endothermic which is misleading. 
The reaction is exothermic. However, as the heats of ionization of the buffer increased, its 
contribution to the observed enthalpy grew to a degree that overwhelmed the actual 
binding enthalpy. This exemplifies the importance of determining the intrinsic enthalpy of 
a reaction, especially when there are protonation and deprotonation events occurring. The 
enthalpies associated with the binding of either sisomicin or netilmicin to APH were much 
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smaller than APH with other aminoglycosides where the effects of heats of ionization of 
buffers were smaller.  
The formation of the ternary complexes with sisomicin and netilmicin had no effect, or the 
opposite effect on enthalpy change as compared to the formation of ternary complexes 
with APH and other aminoglycosides studies to date. An increase in favorable entropy, as 
seen here, could be attributed to an increase in disorder of water. This may mean that the 
binding of sisomicin or netilmicin with APH caused a release of more water molecules than 
previously seen with other aminoglycosides. It is important to note that APH was able to 
accommodate for these structural differences, unlike AAC-IIa, and we attribute this 
difference to the flexibility of APH.     
In the future, the binary and ternary APH complexes with sisomicin can be further explored 
with hydrogen-deuterium exchange experiments on NMR to look at the protection of 
specific amino acids from exchange. HSQC and hydrogen-deuterium exchange NMR 
experiments could be performed with APH and netilmicin to determine if similar gain in 
structure is observed with the APH-netilmicin binary complex. DSC experiments could also 
be performed on APH-netilmicin complexes to compare melting temperatures of the 
various complexes. This would directly look at the effect of the additional methyl group 
located on netilmicin’s unprimed sugar ring. It was found during this project that AAC-IIa 
and not AAC-IIIb is able to modify netilmicin, and therefore kinetic and thermodynamic 
parameters could be examined with AAC-IIa and netilmicin. HSQC NMR experiments with 
AAC-IIa and netilmicin would provide insight into the effect of the methyl group on the 
unprimed ring of netilmicin and its effect on the structure of this binary complex in terms 
of gain in structure or flexibility. Netilmicin is a relatively unexplored aminoglycoside and it 
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